Metagenomi Therapeutics Gross Margin 2022-2026 | MGX

Current and historical gross margin for Metagenomi Therapeutics (MGX) over the last 10 years. The current gross profit margin for Metagenomi Therapeutics as of March 31, 2026 is %.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Metagenomi Therapeutics Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2026-03-31 $0.02B $0.02B 100.00%
2025-12-31 $0.03B $0.03B 100.00%
2025-09-30 $0.03B $0.03B 100.00%
2025-06-30 $0.04B $0.04B 100.00%
2025-03-31 $0.05B $0.05B 100.00%
2024-12-31 $0.05B $0.05B 100.00%
2024-09-30 $0.06B $0.06B 100.00%
2024-06-30 $0.06B $0.06B 100.00%
2024-03-31 $0.05B $0.05B 100.00%
2023-12-31 $0.04B $0.04B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.052B $0.025B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00